Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation
NCT00143117
Last updated date
ABOUT THIS STUDY
To determine whether UK-390,957 is an effective and safe treatment for premature ejaculation.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
Ejaculation
Sex
Male
Age
18 + years
Inclusion Criteria
Show details
- Premature ejaculation as defined by DSM-IV
Exclusion Criteria
Show details
- History of erectile dysfunction
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
EjaculationAssessment Of Efficacy and Safety Of UK-390,957 In Men With Premature Ejaculation
NCT00219583
- Bondi Junction, New South Wales
- St Leonards, New South Wales
- Spring Hill, Queensland
- Adelaide, South Australia
- Malvern, Victoria
- Nedlands, Western Australia
- Mistelbach,
- Salzburg,
- Edmonton, Alberta
- Victoria, British Columbia
- London, Ontario
- Oakville, Ontario
- Toronto, Ontario
- Montreal, Quebec
- Montréal, Quebec
- Brno,
- Hradec Kralove,
- Prague 5,
- Praha 2,
- Le Kremlin Bicetre,
- Lyon Cedex 03,
- Muenchen, Bavaria
- Hamburg,
- Hannover,
- Muenchen,
- Beer Sheba,
- Haifa,
- Jerusalem,
- Tel Hashomer,
- Tel- Aviv,
- Milan,
- Roma,
- Den Haag,
- Nijmegen,
- Bodø,
- Moelv,
- Oslo,
- Bialystok,
- Kielce,
- Myslowice,
- Warszawa,
- Sabadell, Barcelona
- Barcelona,
- Madrid,
- Malaga,
- Skovde,
- Stockholm,
- Balcali, Adana
- Samanpazari, Ankara
- Balcova, Izmir
Male
18 Years+
years
MULTIPLE SITES
EjaculationAssessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation
NCT00143117
- Tucson, Arizona
- Anaheim, California
- Atherton, California
- Beverly Hills, California
- Laguna Woods, California
- Newport Beach, California
- Redwood City, California
- San Diego, California
- Tarzana, California
- Walnut Creek, California
- Aurora, Colorado
- Waterbury, Connecticut
- Aventura, Florida
- New Port Richey, Florida
- Pembroke Pines, Florida
- Evansville, Indiana
- Fort Wayne, Indiana
- Indianapolis, Indiana
- Michigan City, Indiana
- Lexington, Kentucky
- Madisonville, Kentucky
- Metairie, Louisiana
- Milford, Massachusetts
- St. Clair Shores, Michigan
- Minneapolis, Minnesota
- Southhaven, Mississippi
- Kansas City, Missouri
- Reno, Nevada
- Edison, New Jersey
- New Brunswick, New Jersey
- Voorhees, New Jersey
- Albany, New York
- Endwell, New York
- New York, New York
- West Seneca, New York
- Williamsville, New York
- Charlotte, North Carolina
- Durham, North Carolina
- Beachwood, Ohio
- Tulsa, Oklahoma
- Germantown, Tennessee
- Knoxville, Tennessee
- Memphis, Tennessee
- Milan, Tennessee
- Dallas, Texas
- Fort Worth, Texas
- Houston, Texas
- Plano, Texas
- San Antonio, Texas
- Tacoma, Washington
- Milwaukee, Wisconsin
Male
18 Years+
years
MULTIPLE SITES
EjaculationAssessment Of Efficacy and Safety UK-390,957 In Men With Premature Ejaculation
NCT00219635
- Birmingham, Alabama
- San Bernardino, California
- Metairie, Louisiana
- Watertown, Massachusetts
- Kansas City, Missouri
- Washington, Missouri
- New York, New York
- Williamsville, New York
- Beachwood, Ohio
- Portland, Oregon
- Knoxville, Tennessee
- Dallas, Texas
- Houston, Texas
- Milwaukee, Wisconsin
- St Leonards, New South Wales
- Malvern, Victoria
- Victoria, British Columbia
- Barrie, Ontario
- London, Ontario
- Toronto, Ontario
- Nr Lichfield, Staffordshire
- Devon,
Male
18 Years+
years
MULTIPLE SITES
EjaculationAssessment Of Safety Of UK-390,957
NCT00219609
- Tucson, Arizona
- Anaheim, California
- Atherton, California
- Beverly Hills, California
- Laguna Woods, California
- Newport Beach, California
- Redwood City, California
- San Diego, California
- Tarzana, California
- Walnut Creek, California
- Aurora, Colorado
- Waterbury, Connecticut
- Aventura, Florida
- New Port Richey, Florida
- Evansville, Indiana
- Fort Wayne, Indiana
- Indianapolis, Indiana
- Lexington, Kentucky
- Madisonville, Kentucky
- Metairie, Louisiana
- Watertown, Massachusetts
- Saint Clair Shores, Michigan
- Minneapolis, Minnesota
- Southhaven, Mississippi
- Kansas City, Missouri
- Edison, New Jersey
- New Brunswick, New Jersey
- Vorhees, New Jersey
- Albany, New York
- Endwell, New York
- New York, New York
- West Seneca, New York
- Williamsville, New York
- Charlotte, North Carolina
- Durham, North Carolina
- Beachwood, Ohio
- Portland, Oregon
- Germantown, Tennessee
- Knoxville, Tennessee
- Memphis, Tennessee
- Milan, Tennessee
- Dallas, Texas
- Houston, Texas
- San Antonio, Texas
- Milwaukee, Wisconsin
- Milwuakee, Wisconsin
- St Leonards, New South Wales
- Spring Hill, Queensland
- Adelaide, South Australia
- Malvern, Victoria
- Nedlands, Western Australia
- Mistelbach,
- Salzburg,
- Barrie, Ontario
- London, Ontario
- Oakville, Ontario
- Toronto, Ontario
- Montreal, Quebec
- Montréal, Quebec
- Brno,
- Prague 5,
- Praha 2,
- Lyon Cedex 03,
- Hamburg,
- Hannover,
- Muenchen,
- Beer Sheba,
- Haifa,
- Tel Hashomer,
- Tel-Aviv,
- Milan,
- Roma,
- Moelv,
- Oslo,
- Myslowice,
- Warszawa,
- Skovde,
- Stockholm,
- Balcali, Adana
- Samanpazari, Ankara
- Balcova, Izmir
- Nr Lichfield, Staffordshire
- Devon,
Male
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation | |||
Official Title ICMJE | A Phase 2b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Dose Response Study to Assess the Efficacy and Safety of Oral UK-390,957 in Men With Premature Ejaculation | |||
Brief Summary | To determine whether UK-390,957 is an effective and safe treatment for premature ejaculation. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 2 Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Primary Purpose: Treatment | |||
Condition ICMJE | Ejaculation | |||
Intervention ICMJE | Drug: UK-390,957 | |||
Study Arms ICMJE | Not Provided | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Enrollment ICMJE | 460 | |||
Original Enrollment ICMJE | Same as current | |||
Actual Study Completion Date ICMJE | June 2005 | |||
Actual Primary Completion Date | June 2005 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00143117 | |||
Other Study ID Numbers ICMJE | A3871022 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Pfizer | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | November 2012 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |